These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 23890930)

  • 1. Vascular priming enhances chemotherapeutic efficacy against head and neck cancer.
    Folaron M; Kalmuk J; Lockwood J; Frangou C; Vokes J; Turowski SG; Merzianu M; Rigual NR; Sullivan-Nasca M; Kuriakose MA; Hicks WL; Singh AK; Seshadri M
    Oral Oncol; 2013 Sep; 49(9):893-902. PubMed ID: 23890930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid against human head and neck carcinoma xenografts.
    Seshadri M; Mazurchuk R; Spernyak JA; Bhattacharya A; Rustum YM; Bellnier DA
    Neoplasia; 2006 Jul; 8(7):534-42. PubMed ID: 16867215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring antivascular therapy in head and neck cancer xenografts using contrast-enhanced MR and US imaging.
    Seshadri M; Sacadura NT; Coulthard T
    Angiogenesis; 2011 Dec; 14(4):491-501. PubMed ID: 21901534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bevacizumab enhances the therapeutic efficacy of Irinotecan against human head and neck squamous cell carcinoma xenografts.
    Cao S; Durrani FA; Toth K; Rustum YM; Seshadri M
    Oral Oncol; 2011 Jun; 47(6):459-66. PubMed ID: 21530364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor vascular response to photodynamic therapy and the antivascular agent 5,6-dimethylxanthenone-4-acetic acid: implications for combination therapy.
    Seshadri M; Spernyak JA; Mazurchuk R; Camacho SH; Oseroff AR; Cheney RT; Bellnier DA
    Clin Cancer Res; 2005 Jun; 11(11):4241-50. PubMed ID: 15930363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The vascular disrupting agent ombrabulin (AVE8062) enhances the efficacy of standard therapies in head and neck squamous cell carcinoma xenograft models.
    Clémenson C; Jouannot E; Merino-Trigo A; Rubin-Carrez C; Deutsch E
    Invest New Drugs; 2013 Apr; 31(2):273-84. PubMed ID: 22810221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MRI-based characterization of vascular disruption by 5,6-dimethylxanthenone-acetic acid in gliomas.
    Seshadri M; Ciesielski MJ
    J Cereb Blood Flow Metab; 2009 Aug; 29(8):1373-82. PubMed ID: 19458603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical Activity of the Vascular Disrupting Agent OXi4503 against Head and Neck Cancer.
    Bothwell KD; Folaron M; Seshadri M
    Cancers (Basel); 2016 Jan; 8(1):. PubMed ID: 26751478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of the early effects of 5,6-dimethylxanthenone-4-acetic acid using macromolecular contrast media-enhanced magnetic resonance imaging: ectopic versus orthotopic tumors.
    Seshadri M; Bellnier DA; Cheney RT
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(4):1198-207. PubMed ID: 18954713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vascular disruption in combination with mTOR inhibition in renal cell carcinoma.
    Ellis L; Shah P; Hammers H; Lehet K; Sotomayor P; Azabdaftari G; Seshadri M; Pili R
    Mol Cancer Ther; 2012 Feb; 11(2):383-92. PubMed ID: 22084164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid improves the antitumor efficacy and shortens treatment time associated with Photochlor-sensitized photodynamic therapy in vivo.
    Seshadri M; Bellnier DA
    Photochem Photobiol; 2009; 85(1):50-6. PubMed ID: 18643909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Visualizing the acute effects of vascular-targeted therapy in vivo using intravital microscopy and magnetic resonance imaging: correlation with endothelial apoptosis, cytokine induction, and treatment outcome.
    Seshadri M; Spernyak JA; Maiery PG; Cheney RT; Mazurchuk R; Bellnier DA
    Neoplasia; 2007 Feb; 9(2):128-35. PubMed ID: 17356709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-8 as a modulator of response to bevacizumab in preclinical models of head and neck squamous cell carcinoma.
    Gyanchandani R; Sano D; Ortega Alves MV; Klein JD; Knapick BA; Oh S; Myers JN; Kim S
    Oral Oncol; 2013 Aug; 49(8):761-70. PubMed ID: 23623402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneously inactivating Src and AKT by saracatinib/capivasertib co-delivery nanoparticles to improve the efficacy of anti-Src therapy in head and neck squamous cell carcinoma.
    Lang L; Shay C; Zhao X; Xiong Y; Wang X; Teng Y
    J Hematol Oncol; 2019 Dec; 12(1):132. PubMed ID: 31805962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma.
    Jassar AS; Suzuki E; Kapoor V; Sun J; Silverberg MB; Cheung L; Burdick MD; Strieter RM; Ching LM; Kaiser LR; Albelda SM
    Cancer Res; 2005 Dec; 65(24):11752-61. PubMed ID: 16357188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute vascular disruption by 5,6-dimethylxanthenone-4-acetic Acid in an orthotopic model of human head and neck cancer.
    Seshadri M; Toth K
    Transl Oncol; 2009 Aug; 2(3):121-7. PubMed ID: 19701496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Profiling the Stromal and Vascular Heterogeneity in Patient-derived Xenograft Models of Head and Neck Cancer: Impact on Therapeutic Response.
    Folaron M; Merzianu M; Duvvuri U; Ferris RL; Seshadri M
    Cancers (Basel); 2019 Jul; 11(7):. PubMed ID: 31284584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of mTOR and EGFR targeting in an orthotopic xenograft model of head and neck cancer.
    Bozec A; Ebran N; Radosevic-Robin N; Sudaka A; Monteverde M; Toussan N; Etienne-Grimaldi MC; Nigro CL; Merlano M; Penault-Llorca F; Milano G
    Laryngoscope; 2016 Apr; 126(4):E156-63. PubMed ID: 26597440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic antitumor effect of AAV-mediated TRAIL expression combined with cisplatin on head and neck squamous cell carcinoma.
    Jiang M; Liu Z; Xiang Y; Ma H; Liu S; Liu Y; Zheng D
    BMC Cancer; 2011 Feb; 11():54. PubMed ID: 21291526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-tumor effects of bevacizumab in combination with paclitaxel on head and neck squamous cell carcinoma.
    Fujita K; Sano D; Kimura M; Yamashita Y; Kawakami M; Ishiguro Y; Nishimura G; Matsuda H; Tsukuda M
    Oncol Rep; 2007 Jul; 18(1):47-51. PubMed ID: 17549344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.